Novadoz Pharmaceuticals Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Novadoz Pharmaceuticals Llc Pharmaceutical Import Records from India — 8 Products, $33.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Novadoz Pharmaceuticals Llc — Pharmaceutical Importer Profile (2026) | 8 Products, $33.4M Trade | TransData Nexus

Novadoz Pharmaceuticals Llc

Pharmaceutical Importer · United States · Cardiovascular Focus · $33.4M Total Trade · DGFT Verified

Novadoz Pharmaceuticals Llc is a pharmaceutical importer based in United States with a total trade value of $33.4M across 8 products in 5 therapeutic categories. Based on 1,110 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Novadoz Pharmaceuticals Llc sources from 1 verified Indian supplier, with Msn Laboratories Private Limited accounting for 100.0% of imports.

Novadoz Pharmaceuticals Llc — Import Portfolio & Supplier Network

Novadoz Pharmaceuticals Llc import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Novadoz Pharmaceuticals Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Msn Laboratories Private Limited	$76.7M	2,914	100.0%

Novadoz Pharmaceuticals Llc sources from 1 verified Indian supplier across 1,113 distinct formulations. The sourcing is highly concentrated — Msn Laboratories Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Novadoz Pharmaceuticals Llc Import?

Formulation	Value	Ships
Atorvastatin tablets 40MG 1000's	$1.5M	39
Abiraterone acetate tablets USP 250MG ndc no	$1.0M	51
Atorvastatin tablets 40MG	$751.8K	16
Pregabalin capsules 150MG	$674.4K	28
Abiraterone acetate tablets USP 250 MG ndc	$607.2K	13
Atorvastatin tablets 40MG 1000's	$603.2K	20
Levetiracetam tabs 500MG 120's	$601.7K	14
Msn pharma rosuvastatin tablets USP	$550.0K	11
Atorvastatin tablets 40MG 1000s novadozndc no	$538.5K	15
Pregabalin capsules 200MG	$518.6K	19
Abiraterone acetate tablets USP 250MG 120	$507.0K	11
Fosaprepitant ledta INJ 150MG/vial novandc	$505.6K	12
Abiraterone acetate tablets USP 250 MG	$499.2K	10
Levetiracetam tabs 1000MG 60's	$492.0K	15
Atorvastatin tablets 20MG 1000's	$471.3K	16

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atorvastatin	Cardiovascular	$17.3M	549	1.6%	8
2	Rosuvastatin	Cardiovascular	$6.5M	130	1.4%	12
3	Losartan	Cardiovascular	$5.1M	279	1.7%	6
4	Capecitabine	Advanced Oncology	$3.0M	117	3.4%	3
5	Paclitaxel	Oncology	$787.0K	16	0.9%	13
6	Febuxostat	Lipid & Metabolism	$450.0K	9	0.9%	10
7	Moxifloxacin	Advanced Antibiotics	$249.6K	8	0.8%	19
8	Erlotinib	Advanced Oncology	$35.7K	2	1.3%	14

Novadoz Pharmaceuticals Llc imports 8 pharmaceutical products across 5 categories into United States totaling $33.4M.

Novadoz Pharmaceuticals Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Novadoz Pharmaceuticals LLC is a U.S.-based pharmaceutical company specializing in the marketing and distribution of generic pharmaceuticals. Established as the sales and marketing subsidiary for MSN Labs, a global leader in the development and manufacturing of active pharmaceutical ingredients (APIs), Novadoz focuses on providing safe, effective, and affordable generic medications to the U.S. market.

Headquartered in Piscataway, New Jersey, Novadoz operates as the North American arm of MSN Labs, leveraging its parent company's extensive capabilities in API production and finished dosage forms. This strategic partnership enables Novadoz to offer a diverse portfolio of generic drugs, including oral solids, injectables, and specialty products, ensuring a consistent supply of high-quality pharmaceuticals to meet the needs of healthcare providers and patients across the United States.

2Distribution Network

Novadoz Pharmaceuticals maintains a robust distribution network to effectively serve the U.S. market. The company operates a state-of-the-art manufacturing facility in Piscataway, New Jersey, which received FDA clearance in December 2021. This facility is equipped to produce high-quality generic pharmaceuticals, including both oral solids and liquids, and houses modern laboratories and executive offices for MSN Pharmaceuticals and Novadoz Pharmaceuticals.

In addition to its manufacturing capabilities, Novadoz collaborates with various logistics partners to ensure efficient distribution of its products nationwide. The company's strategic location in New Jersey facilitates access to major transportation hubs, enhancing its ability to deliver products promptly to healthcare providers and pharmacies across the United States.

3Industry Role

Novadoz Pharmaceuticals LLC serves as a key player in the U.S. pharmaceutical supply chain, primarily functioning as a wholesaler and distributor of generic medications. By marketing and distributing MSN Labs' portfolio of finished dosage forms, Novadoz ensures a steady supply of affordable and high-quality generic drugs to the U.S. market. This role is crucial in providing healthcare providers and patients with accessible treatment options, thereby contributing to the overall efficiency and affordability of the U.S. healthcare system.

The company's focus on generic pharmaceuticals aligns with the industry's emphasis on cost-effective healthcare solutions. Through its strategic partnerships and distribution channels, Novadoz plays a significant role in enhancing the availability of generic drugs, supporting the sustainability and resilience of the pharmaceutical supply chain in the United States.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Novadoz Pharmaceuticals Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Novadoz Pharmaceuticals exhibits a high degree of sourcing concentration, importing a substantial majority of its finished pharmaceutical formulations from a single supplier, MSN Laboratories Private Limited. Between 2022 and 2026, Novadoz imported approximately $33.4 million worth of products from India, with MSN Laboratories accounting for 100% of these shipments.

This single-source dependency presents both strategic advantages and potential risks. On the positive side, a concentrated sourcing strategy can lead to stronger supplier relationships, streamlined logistics, and potential cost savings. MSN Laboratories' vertical integration, encompassing the production of APIs, key starting materials (KSMs), and finished dosage forms, further enhances the reliability and quality of the supply chain.

However, the lack of supplier diversification also exposes Novadoz to risks such as supply disruptions due to unforeseen events affecting MSN Laboratories. The absence of alternative suppliers could lead to challenges in maintaining consistent product availability and meeting market demand. Therefore, while the current sourcing strategy has facilitated operational efficiencies, it is essential for Novadoz to assess and mitigate potential risks associated with this concentration.

2Supply Chain Resilience

Novadoz Pharmaceuticals' supply chain resilience is closely tied to its exclusive partnership with MSN Laboratories Private Limited. This relationship ensures a consistent and high-quality supply of finished pharmaceutical formulations, as MSN Laboratories' vertical integration spans the production of APIs, KSMs, and finished dosage forms.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the approval and monitoring of pharmaceutical products, including imports. The FDA ensures that all drugs marketed in the U.S. meet safety, efficacy, and quality standards.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal framework for the FDA's regulatory activities. The Drug Approval Process, as outlined by the FDA, involves rigorous evaluation of clinical data to assess the safety and efficacy of new drugs before they can be marketed.

For Indian generic manufacturers aiming to export to the U.S., obtaining an Abbreviated New Drug Application (ANDA) approval from the FDA is essential. This process requires demonstrating bioequivalence to the reference listed drug, ensuring that the generic product performs in the same manner as the innovator drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. are governed by the FDA. Manufacturers and distributors must register with the FDA and comply with the Drug Establishment Registration and Drug Listing requirements. Additionally, imported drugs must adhere to the FDA's Good Manufacturing Practice (GMP) regulations, which ensure that products are consistently produced and controlled according to quality standards.

Novadoz Pharmaceuticals Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Novadoz Pharmaceuticals' product strategy focuses on therapeutic areas with high unmet needs and significant market demand. The company's portfolio includes cardiovascular medications, such as atorvastatin and rosuvastatin, which are widely prescribed for managing cholesterol levels and reducing the risk of cardiovascular events.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Novadoz Pharmaceuticals Llc

What products does Novadoz Pharmaceuticals Llc import from India?

Novadoz Pharmaceuticals Llc imports 8 pharmaceutical products across 5 categories. Top imports: Atorvastatin ($17.3M), Rosuvastatin ($6.5M), Losartan ($5.1M), Capecitabine ($3.0M), Paclitaxel ($787.0K).

Who supplies pharmaceuticals to Novadoz Pharmaceuticals Llc from India?

Novadoz Pharmaceuticals Llc sources from 1 verified Indian suppliers. The primary supplier is Msn Laboratories Private Limited (100.0% of imports, $76.7M).

What is Novadoz Pharmaceuticals Llc's total pharmaceutical import value?

Novadoz Pharmaceuticals Llc's total pharmaceutical import value from India is $33.4M, based on 1,110 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Novadoz Pharmaceuticals Llc focus on?

Novadoz Pharmaceuticals Llc imports across 5 categories. The largest: Cardiovascular (86.4%), Advanced Oncology (9.1%), Oncology (2.4%).

Get Full Novadoz Pharmaceuticals Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.